Swine flu

Jump to navigation Jump to search

Template:Flu

WikiDoc Resources for Swine flu

Articles

Most recent articles on Swine flu

Most cited articles on Swine flu

Review articles on Swine flu

Articles on Swine flu in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Swine flu

Images of Swine flu

Photos of Swine flu

Podcasts & MP3s on Swine flu

Videos on Swine flu

Evidence Based Medicine

Cochrane Collaboration on Swine flu

Bandolier on Swine flu

TRIP on Swine flu

Clinical Trials

Ongoing Trials on Swine flu at Clinical Trials.gov

Trial results on Swine flu

Clinical Trials on Swine flu at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Swine flu

NICE Guidance on Swine flu

NHS PRODIGY Guidance

FDA on Swine flu

CDC on Swine flu

Books

Books on Swine flu

News

Swine flu in the news

Be alerted to news on Swine flu

News trends on Swine flu

Commentary

Blogs on Swine flu

Definitions

Definitions of Swine flu

Patient Resources / Community

Patient resources on Swine flu

Discussion groups on Swine flu

Patient Handouts on Swine flu

Directions to Hospitals Treating Swine flu

Risk calculators and risk factors for Swine flu

Healthcare Provider Resources

Symptoms of Swine flu

Causes & Risk Factors for Swine flu

Diagnostic studies for Swine flu

Treatment of Swine flu

Continuing Medical Education (CME)

CME Programs on Swine flu

International

Swine flu en Espanol

Swine flu en Francais

Business

Swine flu in the Marketplace

Patents on Swine flu

Experimental / Informatics

List of terms related to Swine flu

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Swine influenza (also swine flu) refers to influenza caused by any virus of the family Orthomyxoviridae, that is endemic to pig (swine) populations. Strains endemic in swine are called swine influenza virus (SIV), and all known strains of SIV are classified as Influenzavirus A (common) or Influenzavirus C (rare).[1] Influenzavirus B has not been reported in swine. All three clades, Influenzavirus A, B, and C, are endemic in humans.

People who work with poultry and swine, especially people with intense exposures, are at risk of infection from these animals if the animals carry a strain that is also able to infect humans. SIV can mutate into a form that allows it to pass from human to human. The strain responsible for the 2009 swine flu outbreak is believed to have undergone this mutation.[2]

In humans, the symptoms of swine flu are similar to those of influenza and of influenza-like illness in general.

Classification

SIV strains isolated to date have been classified either as Influenzavirus C or one of the various subtypes of the genus Influenzavirus A.[3]

Influenza A

Swine influenza is known to be caused by influenza A subtypes H1N1,[4] H1N2,[4] H3N1,[5] H3N2,[4] and H2N3.[6]

In swine, three influenza A virus subtypes (H1N1, H3N2, and H1N2) are circulating throughout the world. In the United States, the H1N1 subtype was exclusively prevalent among swine populations before 1998; however, since late August 1998, H3N2 subtypes have been isolated from pigs. As of 2004, H3N2 virus isolates in US swine and turkey stocks were triple reassortants, containing genes from human (HA, NA, and PB1), swine (NS, NP, and M), and avian (PB2 and PA) lineages.[7]

Interaction With H5N1

Avian influenza virus H3N2 is endemic in pigs in China and has been detected in pigs in Vietnam, increasing fears of the emergence of new variant strains.[8] Health experts say pigs can carry human influenza viruses, which can combine (i.e. exchange homologous genome sub-units by genetic reassortment) with H5N1, passing genes and mutating into a form which can pass easily among humans.[9] H3N2 evolved from H2N2 by antigenic shift.[10] In August 2004, researchers in China found H5N1 in pigs.[11]

General Management and & Treatment

The aim is to provide interim guidance on the use of antiviral agents for treatment and chemoprophylaxis of swine influenza A (H1N1) virus infection. This includes patients with confirmed or suspected swine influenza A (H1N1) virus infection and their close contacts.

Case Definitions for Infection with Swine Influenza A (H1N1) Virus

A confirmed case of swine influenza A (H1N1) virus infection is defined as a person with an acute febrile respiratory illness with laboratory confirmed swine influenza A (H1N1) virus infection at CDC by one or more of the following tests:

1. real-time RT-PCR

2. viral culture

Infectious period

The infectious period for a confirmed case of swine influenza A (H1N1) virus infection is defined as 1 day prior to the case’s illness onset to 7 days after onset.

A probable case of swine influenza A (H1N1) virus infection is defined as a person with an acute febrile respiratory illness who is:

  • positive for influenza A, but negative for H1 and H3 by influenza RT-PCR, or
  • positive for influenza A by an influenza rapid test or an influenza immunofluorescence assay (IFA) plus meets criteria for a suspected case

A suspected case of swine influenza A (H1N1) virus infection is defined as a person with acute febrile respiratory illness with onset

  • within 7 days of close contact with a person who is a confirmed case of swine influenza A (H1N1) virus infection, or
  • within 7 days of travel to community either within the United States or internationally where there are one or more confirmed swine influenza A (H1N1) cases, or
  • resides in a community where there are one or more confirmed swine influenza cases.

Close contact is defined as: within about 6 feet of an ill person who is a confirmed or suspected case of swine influenza A (H1N1) virus infection during the case’s infectious period.

Acute respiratory illness is defined as: recent onset of at least two of the following: rhinorrhea or nasal congestion, sore throat, cough (with or without fever or feverishness)

High-risk group for complications of influenza is defined as: a person who is at high-risk for complications of seasonal influenza: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e717a1.htm.However, it too early to ascertain what persons are at high-risk for complications of swine influenza A(H1N1) virus infection. This guidance will be updated as new information is available.

Clinicians should consider swine influenza A (H1N1) virus infection in the differential diagnosis of patients with febrile respiratory disease and who 1) live in areas in the U.S. with confirmed human cases of swine influenza A (H1N1) virus infection or 2) who traveled recently to Mexico or were in contact with persons who had febrile respiratory illness and were in the areas of the U.S. with confirmed swine influenza cases or Mexico in the 7 days preceding their illness onset.

Special Considerations for Children

Aspirin or aspirin-containing products (e.g. bismuth subsalicylate – Pepto Bismol) should not be administered to any confirmed or suspected ill case of swine influenza A (H1N1) virus infection aged 18 years old and younger due to the risk of Reye syndrome. For relief of fever, other anti-pyretic medications are recommended such as acetaminophen or non steroidal anti-inflammatory drugs.

Antiviral Resistance

This swine influenza A (H1N1) virus is sensitive (susceptible) to the neuraminidaseinhibitor antiviral medications zanamivir and oseltamivir. It is resistant to the adamantane antiviral medications amantadine and rimantadine.

Seasonal influenza A and B viruses continue to circulate at low levels in the U.S. and in Mexico. Currently circulating human influenzaA (H1N1) viruses are resistant to oseltamivir and sensitive (susceptible) to zanamivir, amantadine and rimantadine. Currently circulating human influenza A (H3N2) viruses are resistant to amantadine andrimantadine, but sensitive (susceptible) to oseltamivir and zanamivir. Therefore,at this time antiviral treatment recommendations for suspected cases of swineinfluenza A (H1N1) virus infection need to consider potential infection with swine influenza A (H1N1) virus as wellas human influenza viruses, andtheir different antiviral susceptibilities.

Antiviral Treatment

Suspected Cases

Empiric antiviral treatment is recommended for any ill person suspected to have swine influenza A (H1N1) virus infection. Antiviral treatment witheither zanamivir alone or with a combination of oseltamivir and either amantadine or rimantadine should be initiated as soon as possible after theonset of symptoms. Recommended duration of treatment is five days.Recommendations for use of antivirals may change as data on antiviral susceptibilities become available. Antiviral doses and schedules recommended for treatment of swine influenza A (H1N1) virus infection are the same as those recommended for seasonal influenza: http://www.cdc.gov/flu/professionals/antivirals/dosagetable.htm#table

Confirmed Cases

For antiviral treatment of a confirmed case of swine influenza A (H1N1) virus infection, either oseltamivir or zanamivir may be administered. Recommended duration of treatment is five days.These same antivirals should be considered for treatment of cases that test positive for influenza A but test negative for seasonal influenza viruses H3 and H1 by PCR.

Pregnant Women

Oseltamivir, zanamivir, amantadine, and rimantadine are all “PregnancyCategory C" medications, indicating that no clinical studies have beenconducted to assess the safety of these medications for pregnant women. Onlytwo cases of amantadine use for severe influenza illness during the thirdtrimester have been reported. However, both amantadine and rimantadine havebeen demonstrated in animal studies to be teratogenic and embryotoxic whenadministered at substantially high doses. Because of the unknown effects ofinfluenza antiviral drugs on pregnant women and their fetuses, these four drugsshould be used during pregnancy only if the potential benefit justifies thepotential risk to the embryo or fetus; the manufacturers' package insertsshould be consulted. However, no adverse effects have been reported among womenwho received oseltamivir or zanamivir during pregnancy or among infants born to such women.

Antiviral Chemoprophylaxis

For antiviral chemoprophylaxis of swine influenza A (H1N1) virus infection,either oseltamivir or zanamivir are recommended. Duration of antiviralchemoprophylaxis is 7 days after the last known exposure to an ill confirmedcase of swine influenza A (H1N1) virus infection. Antiviral dosing and schedules recommended for chemoprophylaxis of swine influenza A(H1N1) virus infection are the same as those recommended for {http://www.cdc.gov/flu/professionals/antivirals/dosagetable.htm#table seasonal influenza]:

Antiviral chemoprophylaxis (pre-exposure or post-exposure) with eitheroseltamivir or zanamivir is recommended for the followingindividuals:

  • Household close contacts who are at high-risk for complications of influenza (persons with certain chronic medical conditions, elderly) of a confirmed or suspected case.
  • School children who are at high-risk for complications of influenza (persons with certain chronic medical conditions) who had close contact (face-to-face) with a confirmed or suspected case.
  • Travelers to Mexico who are at high-risk for complications of influenza (persons with certain chronic medical conditions, elderly).
  • Border workers (Mexico) who are at high-risk for complications of influenza (persons with certain chronic medical conditions, elderly).
  • Health care workers or public health workers who had unprotected close contact with an ill confirmed case of swine influenza A (H1N1) virus infection during the case’s infectious period.

Antiviral chemoprophylaxis (pre-exposure or post-exposure) with either oseltamivir or zanamivir can be considered for the following:

  • Any health care worker who is at high-risk for complications of influenza (persons with certain chronic medical conditions, elderly) who is working in an area with confirmed swine influenza A (H1N1) cases, and who is caring for patients with any acute febrile respiratory illness.

8 Non-high risk persons who are travelers to Mexico, first responders, or border workers who are working in areas with confirmed cases of swine influenza A (H1N1) virus infection.

References

  1. Heinen PP (15 September 2003). "Swine influenza: a zoonosis". Veterinary Sciences Tomorrow. ISSN 1569-0830. Influenza B and C viruses are almost exclusively isolated from man, although influenza C virus has also been isolated from pigs and influenza B has recently been isolated from seals.
  2. http://www.who.int/mediacentre/news/statements/2009/h1n1_20090427/en/index.html
  3. Heinen PP (15 September 2003). "Swine influenza: a zoonosis". Veterinary Sciences Tomorrow. ISSN 1569-0830. Influenza B and C viruses are almost exclusively isolated from man, although influenza C virus has also been isolated from pigs and influenza B has recently been isolated from seals.
  4. 4.0 4.1 4.2 "Swine Influenza". Swine Diseases (Chest). Iowa State University College of Veterinary Medicine.
  5. Shin JY, Song MS, Lee EH, Lee YM, Kim SY, Kim HK, Choi JK, Kim CJ, Webby RJ, Choi YK (2006). "Isolation and characterization of novel H3N1 swine influenza viruses from pigs with respiratory diseases in Korea". Journal of Clinical Microbiology. 44 (11): 3923–7. doi:10.1128/JCM.00904-06. PMID 16928961.
  6. Ma W, Vincent AL, Gramer MR, Brockwell CB, Lager KM, Janke BH, Gauger PC, Patnayak DP, Webby RJ, Richt JA (26 December 2007). "Identification of H2N3 influenza A viruses from swine in the United States". Proc Nat Acad Sci U S A. 104 (52): 20949–54. doi:10.1073/pnas.0710286104. PMC 2409247. PMID 18093945.
  7. Yassine HM, Al-Natour MQ, Lee CW, Saif YM (2007). "Interspecies and intraspecies transmission of triple reassortant H3N2 influenza A viruses". Virol J. 28 (4): 129. doi:10.1186/1743-422X-4-129. PMC 2228287. PMID 18045494. Unknown parameter |month= ignored (help)
  8. Yu, H. (2008). "Genetic evolution of swine influenza A (H3N2) viruses in China from 1970 to 2006". Journal of Clinical Microbiology. 46 (3): 1067. doi:10.1128/JCM.01257-07. PMID 18199784. Unknown parameter |month= ignored (help)
  9. "Bird flu and pandemic influenza: what are the risks?". UK Department of Health.
  10. Lindstrom Stephen E, Cox Nancy J, Klimov Alexander (15 October 2004). "Genetic analysis of human H2N2 and early H3N2 influenza viruses, 1957–1972: evidence for genetic divergence and multiple reassortment events". Virology. 328 (1): 101–19. doi:10.1016/j.virol.2004.06.009. PMID 15380362.
  11. World Health Organization (28 October 2005). "H5N1 avian influenza: timeline" (PDF).

Template:SIB

Influenza Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Swine flu On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Swine flu

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Swine flu

CDC on Swine flu

Swine flu in the news

Blogs on Swine flu

Directions to Hospitals Treating Influenza

Risk calculators and risk factors for Swine flu


Template:WH Template:WS